At a
Glance
2022
“Forward Thinking Healthcare” captures our commitment to the future: ever better medicine for ever more people.
  • Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 300,000 employees in more than 100 countries around the globe and annual sales exceeding €37 billion, Fresenius is one of the world’s leading healthcare companies.

    At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to medical progress and better patient care.

    FRESENIUS INVESTED 818 MILLION IN RESEARCH AND DEVELOPMENT LAST YEAR.
  • Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which more than 3.8 million patients worldwide regularly undergo dialysis treatment.

    Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatments for over 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines and dialyzers.

    Along with its core business, the company offers a wide variety of other health care services and products.

    IN 2021, FRESENIUS MEDICAL CARE PROVIDED AROUND 53 MILLION DIALYSIS TREATMENTS TO PATIENTS.
  • Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.

    In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

    EVERY FOURTH BLOOD DONATION WORLDWIDE IS COLLECTED IN A FRESENIUS KABI BLOOD BAG.
  • Fresenius Helios is Europe’s leading private hospital operator, with more than 120,000 employees. Fresenius Helios includes Helios Kliniken in Germany, Quirónsalud in Spain and Latin America, and the Eugin Group with a global network of reproductive clinics. Every year about 20 million patients choose Fresenius Helios for medical treatment.

    Helios operates 89 acute care hospitals, about 130 outpatient clinics and six prevention centers in Germany. Quirónsalud operates 56 hospitals, including seven in Latin America, 88 outpatient centers and around 300 occupational risk prevention centers. Eugin Group’s network comprises 33 clinics and an additional 39 sites across 10 countries on three continents.

    AROUND 87,000 BIRTHS TAKE PLACE IN FRESENIUS HELIOS HOSPITALS ANNUALLY.
  • Fresenius Vamed is a leading global provider of services for hospitals and other health care facilities. Its portfolio ranges from project development, planning and turnkey construction through to total operational management of health care facilities and providing services to patients. The services are aimed at various areas of health care, ranging from prevention to acute care, rehabilitation, and nursing.

    Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 health care projects in 98 countries on five continents since the company’s founding in 1982.

    FRESENIUS VAMED IS THE LEADING PRIVATE REHABILITATION CARE PROVIDER IN AUSTRIA, THE CZECH REPUBLIK, GERMANY AND SWIZERLAND, WITH MORE THAN 8,200 BEDS.
  • +2 %
    -2 %
    +2 %
    +6 %
    +2 %
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
    Fresenius Vamed
  • € in
    millions
    +5 %
    +2 %
    +4 %
    +11 %
    +11 %
    € in
    millions
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
    Fresenius Vamed
  • € in
    millions
    +5 %
    -23 %
    +8 %
    +10 %
    --- %
    € in
    millions
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
    Fresenius Vamed
  • € in
    millions
    -6 %
    -21 %
    +7 %
    +10 %
    --- %
    € in
    millions
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
    Fresenius Vamed
  • € in
    millions
    -22 %
    -41 %
    +5 %
    +5 %
    +94 %
    € in
    millions
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
    Fresenius Vamed
  • € in
    millions
    -6 %
    +2 %
    -26 %
    +2 %
    -20 %
    € in
    millions
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
    Fresenius Vamed
  • € in
    millions
    +9 %
    +14 %
    +8 %
    +50 %
    € in
    millions
    Fresenius Medical Care
    Fresenius Kabi
    Fresenius Helios
  • +28 %
    +28 %
    Fresenius Vamed
Some figures adjusted for special items; when applicable, changes are in constant currency. Net income = Net income attributable to the parent company of the respective business segment.
  • 316,078
    Employees
    North America
    24 %
    76,740
    Europe
    57 %
    180,122
    Latin America
    and Africa
    10 %
    32,071
    Asia-Pacific
    9 %
    27,145
  • € 37.5 billion
    sales in 2021
    North America
    38 %
    € 14.4 billion
    Europe
    45 %
    € 16.9 billion
    Latin America
    and Africa
    6 %
    € 2.3 billion
    Asia-Pacific
    11 %
    € 3.9 billion

2021 in Review

Happy anniversary!

Fresenius Medical Care celebrates 25 years since its founding. The company marks the occasion with a €250,000 donation to help UNICEF combat the COVID-19 pandemic.

Growth strategy 2025

Fresenius Medical Care transforms its operating model into a simplified structure with just two business segments – to increase the transfer of knowledge and spur growth. The composition of the Management Board is adapted to the new operating model.

Staying fit and helping others

In October, employees worldwide lace up their jogging shoes for a donor run. Fresenius makes a donation on behalf of each participant – and helps more than 70 non-profit organizations.

Hospital network expanded

In September, Fresenius Helios acquires German Red Cross hospitals in the city of Kassel. In November, the company takes over an oncological center and an ophthalmic clinic in Medellin, Colombia.

Modern production

Fresenius Kabi continues to invest in the expansion and modernization of its production plants, including facilities in Austria, China and France.

Fresenius vaccinates

Fresenius Helios administers more than 1 million COVID-19 vaccinations at around 150 facilities. Fresenius Medical Care makes dialysis centers available for vaccinations.

Sustainability

A commitment to operating responsibly and sustainably is part of our company’s business culture, and of the way we work every day. Living up to our legal and ethical responsibilities as a globally active company is important to us.
We therefore adjusted our Management Board compensation system in 2021. In addition to key financial indicators, it now takes into account sustainability targets relating to environmental, social and governance aspects. For this purpose, we have identified the following topic areas:

Patient Well-being
Employees
Compliance
Digitalization & Innovation
Environment

In managing these topic areas, we will also use key performance indicators such as patient satisfaction, medical treatment quality, diversity, and innovation. The Management Board approved these performance indicators last year. They will be compiled and regularly measured starting in 2022.

From a local pharmacy to a global corporation

  • Opening of the Hirsch Pharmacy in Frankfurt

    In the 19th century, ownership of the pharmacy passes to the Fresenius family.

    1462
  • Founding of the company

    The pharmacist Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company Dr. E. Fresenius.

    1912
  • Founder Eduard Fresenius dies

    The unexpected death of Eduard Fresenius endangers the further existence of the pharmacy and manufacturing company, which now has only 40 employees.

    1946
  • Else Kröner assumes management of Fresenius

    The foster daughter of Eduard Fresenius will, along with her future husband Hans Kröner, build the company into a global healthcare group over the following decades.

    1952
  • Distributor of dialysis machines

    Fresenius starts to sell dialysis machines and dialyzers manufactured by various international companies.

    1966
  • Development and sale of company’s own dialysis machines

    Production of the A2008 dialysis machine begins in a newly acquired factory in Schweinfurt, Germany.

    1979
  • Stock market flotation

    Fresenius launches preference shares on the Frankfurt stock exchange.

    1986
  • Entry into project business

    With the acquisition of Hospitalia International, Fresenius enters the project business for developing hospitals and other healthcare facilities. Two years later, Fresenius acquires a majority stake in the hospital services provider VAMED AG.

    1994
  • Entry into Dialysis Services

    Fresenius Medical Care is created when the U.S. dialysis provider National Medical Care, acquired by Fresenius, is merged with Fresenius’ own dialysis business. The project business is expanded with the acquisition of VAMED AG.

    1996
  • Expansion of infusions business

    The nutrition business of Pharmacia & Upjohn is acquired and then merged with Fresenius Pharma to form Fresenius Kabi.

    1999
  • Expansion of hospital business

    Fresenius acquires Helios, one of Germany’s leading private hospital operators.

    2005
  • Expansion in I.V. generics

    Fresenius Kabi enters the North American pharmaceuticals market through the acquisition of APP Pharmaceuticals.

    2008
  • Hospital network expanded outside of Germany

    Fresenius Helios acquires Quirónsalud, Spain’s largest private hospital operator.

    2017
  • Entry into reproductive medicine

    Fresenius Helios takes over the Eugin Group, a leading international group in the field of fertility treatments.

    2021
  • Active around the world

    With more than 300,000 employees in over 100 countries, Fresenius is one of the world’s leading healthcare companies.

    2022

Download our publications

More information on the Fresenius healthcare group

fresenius.com